<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512262</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-019</org_study_id>
    <secondary_id>ATOM</secondary_id>
    <nct_id>NCT03512262</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 12 month study to measure the efficacy and safety of abaloparatide in men with
      osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this prospective controlled study is to evaluate the efficacy and
      the safety of abaloparatide-SC 80 mcg per day compared to placebo as assessed by change in
      bone mineral density over 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized patients will received a 2:1 ratio of abaloparatide:placebo injections.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment will be blinded to participants, investigators, outcome Assessor and care provider throughout the study except in a medical emergency where the identity of study medication is necessary to appropriately treat the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar spine bone mineral density (BMD)</measure>
    <time_frame>12 months</time_frame>
    <description>Percent change from baseline in lumbar spine BMD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total hip BMD</measure>
    <time_frame>12 months</time_frame>
    <description>Percent change from baseline for total hip BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Femoral neck BMD</measure>
    <time_frame>12 months</time_frame>
    <description>Percent change from baseline for femoral neck BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar spine BMD</measure>
    <time_frame>6 months</time_frame>
    <description>Percent change from baseline in lumbar spine BMD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent adverse events (TEAEs) associated with hypercalcemia</measure>
    <time_frame>13 months</time_frame>
    <description>Percent of participants reporting TEAE associated with hypercalcemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Osteoporosis, Age-Related</condition>
  <condition>Osteoporosis Localized to Spine</condition>
  <condition>Age Related Osteoporosis</condition>
  <condition>Osteoporosis Senile</condition>
  <condition>Osteoporosis of Vertebrae</condition>
  <arm_group>
    <arm_group_label>Abaloparatide (BA058)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abaloparatide is an active synthetic peptide of parathyroid hormone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with no peptide of parathyroid hormone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abaloparatide</intervention_name>
    <description>Abaloparatide 80 mcg subcutaneous daily</description>
    <arm_group_label>Abaloparatide (BA058)</arm_group_label>
    <other_name>TYMLOS™, abaloparatide-SC, BA058</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 0 mcg subcutaneous daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA

          -  Healthy ambulatory male from 40 to 85 years of age (inclusive) with primary
             osteoporosis or osteoporosis associated with hypogonadism.

          -  The patient has a BMD T-score (based on the female reference range as assessed by the
             central imaging vendor) of ≤ -2.5 at the lumbar spine (L1-L4) or hip (femoral neck or
             total hip) by DXA or ≤-1.5 and with radiologic evidence of vertebral fracture or a
             documented history of low-trauma nonvertebral fracture sustained in the past 5 years.
             Men older than 65 years may be enrolled if they have a BMD T-score ≤ -2.0 even if they
             do not meet the fracture criteria.

          -  Normal medical history, physical examination, including vital signs, and body mass
             index (BMI).

          -  Hypogonadal patients whose doses of androgens have been stable for at least twelve
             months before randomization are eligible and may continue therapy during the study.

          -  Laboratory tests within the normal range including serum calcium (albumin-corrected),
             PTH, serum phosphorus and alkaline phosphatase, and thyroid stimulating hormone (TSH)
             values.

        EXCLUSION CRITERIA

          -  Presence of abnormalities of the lumbar spine that would prohibit assessment of spinal
             bone mineral density, defined as having at least 2 radiologically evaluable vertebrae
             within L1-L4.

          -  A BMD T-score of ≤-3.5 at the total hip, femoral neck, or lumbar spine based upon the
             female reference range.

          -  Unevaluable hip BMD or patients who have undergone bilateral hip replacement.

          -  Fragility fracture within the prior twelve months.

          -  History of severe vertebral fracture or &gt;2 moderate vertebral fractures.

          -  History of bone disorders (e.g., Paget's disease) other than osteoporosis.

          -  Patients with clinical signs of hypogonadism present at screening who plan to initiate
             testosterone replacement.

          -  History of prior external beam or implant radiation therapy involving the skeleton
             other than radioiodine.

          -  History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular,
             gastrointestinal, endocrine, central nervous system, hematologic or metabolic
             diseases, or immunologic, emotional and/or psychiatric disturbances to a degree that
             would interfere with the interpretation of study data or compromise the safety of the
             patient.

          -  History of Cushing's disease, growth hormone deficiency or excess, hyperthyroidism,
             hypo- or hyperparathyroidism or malabsorptive syndromes within the past year.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sr. Director, Clinical Operations</last_name>
    <role>Study Director</role>
    <affiliation>Radius Health, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Radius Health, Inc.</last_name>
    <phone>617-551-4002</phone>
    <email>info@radiuspharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radius Health, Inc.</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Director</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and hormones. J Mol Endocrinol. 2001 Apr;26(2):79-94. Review.</citation>
    <PMID>11241160</PMID>
  </reference>
  <reference>
    <citation>Mannstadt M, Jüppner H, Gardella TJ. Receptors for PTH and PTHrP: their biological importance and functional properties. Am J Physiol. 1999 Nov;277(5 Pt 2):F665-75. Review.</citation>
    <PMID>10564229</PMID>
  </reference>
  <reference>
    <citation>Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993 Dec;14(6):690-709. Review. Erratum in: Endocr Rev 1994 Apr;15(2):261.</citation>
    <PMID>8119233</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BA058</keyword>
  <keyword>abaloparatide</keyword>
  <keyword>abaloparatide-SC</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>male osteoporosis</keyword>
  <keyword>TYMLOS™</keyword>
  <keyword>fracture</keyword>
  <keyword>bone loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

